# Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan

> **NCT04551989** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 118 (actual)

## Conditions studied

- Churg-Strauss Syndrome
- Eosinophilic Granulomatosis With Polyangiitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04551989
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-11
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-04-27
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551989, "Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04551989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*